Milan criteria in the MELD era – Is it justifiable to extend the limits for orthotopic liver Transplantation?

Mehmet Haluk Morgül  
Universitatsklinikum Münster Klinik für Allgemein- Viszeral- und Transplantationschirurgie

Philipp Felgendreff (✉ P.Felgendreff@gmail.com)  
Universitätsklinikum Jena

Andreas Kienlein  
Schwarzwald-Baar Klinikum Villingen-Schwenningen GmbH

Ulrich Gauger  
BIOTRONIK

Katrin Semmling Semmling  
Universitätsklinikum Leipzig

Hans-Michael Hau  
Universitätsklinikum Carl Gustav Carus

Hans-Michael Tautenhahn  
Universitätsklinikum Jena

Michael Bartels  
HELIOS Park-Klinikum Leipzig

Research

Keywords: liver transplantation, HCC, Milan criteria

Posted Date: April 20th, 2020

DOI: https://doi.org/10.21203/rs.3.rs-21639/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License

Version of Record: A version of this preprint was published on July 7th, 2020. See the published version at https://doi.org/10.1186/s12957-020-01932-6.
Abstract

Background

The Milan criteria (MC) are widely used for the indication of liver transplantation (LTx) in hepatocellular carcinoma (HCC). Good long-term results have also been reported following LTx for patients exceeding the MC. In this article, we compare the overall and recurrence-free survival of our patients fulfilling and exceeding the MC according to the posttransplant histopathological results.

Patients and Methods

Data from 120 patients with HCC (22 females and 98 males) were analyzed. The median patient age was 61 years (Q1, Q3: 54.7, 65.4), and the median MELD score was 11 (Q1, Q3: 8, 15). The median follow-up period was 53 months (Q1, Q3: 16.6, 78). Patients were categorized into established criteria (MC, up-to-seven (UTS), Asan criteria, AFP score), and the outcome of the individual groups was compared.

Results

Seventy-four of 120 patients fulfilled the MC, 86 patients met the UTS criteria, 85 patients fulfilled the Asan criteria, and 79 patients had an AFP score less than or equal to 2. The 1- and 5-year survival rates of all patients were 76.7% and 55.6%, respectively. In total, 14.2% of all patients (5.4% of patients who met the MC, 7% of patients who met the UTS criteria, 5.9% of patients who met the Asan criteria, and 6.3% of patients who had an AFP score less than 2) experienced recurrence.

Conclusions

The outcomes of the patients were comparable to those reported in the current literature. In our population, similar recurrence and survival rates of the patients were noted for patients fulfilling the UTS criteria irrespective of fulfilling or exceeding the MC. Consequently, we consider using UTS criteria as the extended criterion for LTx indication.

Introduction

Liver transplantation (LTx) offers the only curative option for patients suffering from end-stage liver disease. In cases of hepatocellular carcinoma (HCC) with underlying liver cirrhosis, the indication for LTx is a major challenge due to the complicated natural course of this disease. To achieve an adequate distribution of the limited number of donor organs for the patients on the waiting list, it is important to identify the patients who benefit most from LTx with a sufficient prognosis.

Based on tumor-specific characteristics, numerous systems have been established for preoperative assessment of the prognosis of patients with HCC and to verify the indication for LTx \(^1\,^2\). In this regard, the most common selection systems are based on the radiological characterization of HCC tumors. Worldwide, the Milan criteria (MC) are a well-known and widely accepted algorithm for the indication of
LTx in patients with HCC. These criteria are based on the work of Mazzaferro et al., who examined the data of 48 patients with HCC and liver cirrhosis over a median follow-up period of 26 months (range: 9-54 months). These very strict criteria were extended by the same group. The up-to-seven (UTS) criteria (sum of the largest tumor diameter in centimeters and the number of tumors) showed similar outcomes following LTx while liberating the criteria for the indication for LTx.

Although tumor biology seems to be a better predictor of recurrence and survival following transplantation, in the current practice, tumor biology is barely involved in decision making since there is no clinically proven biomarker for this purpose. Only higher alpha-fetoprotein (AFP) levels lead clinicians to be restrictive regarding transplantation. In a recent study, Duvoux et al. proposed a mathematical algorithm based on the AFP level, tumor size and number to assess patient survival and the probability of recurrence following LTx. In a cohort of 435 patients, they showed 5-year recurrence rates of 8.8% vs 50.6% for patients with AFP scores ≤2 and >2, respectively. Simultaneously, the 5-year survival rates were 67.8% and 47.5%, respectively.

Many studies have evaluated the success of LTx beyond the MC-based radiological and biological findings of patients; however, a system extending the MC has not been solely adopted in the transplant society.

Here, we introduce the factors influencing the outcome of LTx in patients with HCC fulfilling and exceeding the MC according to the posttransplant histopathological results. Furthermore, we retrospectively analyzed our cohort for extension of the MC using the UTS, as our institutional standard policy, and the AFP score as a novel system involving tumor biology and the Asan criteria, a posttransplant histological-based prognosis system introduced by Lee et al.

Methods

Study design:

All patients who underwent orthotopic liver transplantation between 1994 and 2013 were enrolled in the database of the Department of Visceral, Transplant, Thoracic and Vascular Surgery at the University of Leipzig. Data were collected and analyzed following approval by the university ethics committee (Application number: 078-14-10032014).

Patients without histological evidence of HCC or patients receiving a living donor transplant, secondary liver transplant or pediatric transplant were excluded from the study. To analyze the overall survival and recurrence-free survival, all patients were classified according to four different scoring systems (MC, UTS, AFP score, Asan) based on the postoperative histological result.

Examination and analysis of laboratory parameters
The biochemical parameters of the patients were obtained from clinical charts, and the Model for End-Stage Liver Disease (MELD) score for each patient was calculated if the parameters necessary for determining the MELD score (bilirubin, creatinine, international normalized ratio of the same sample, receiving renal replacement therapy more than twice in the last week) were available. The most recent AFP level of the patient before transplantation was considered for the analysis.

**HCC diagnosis**

The primary diagnosis of HCC is based only on histological examination. For the assessment of the MC\(^3\), UTS criteria\(^4\), Asan criteria\(^8\) and AFP score\(^6\), the histological results of the explanted livers showing the tumor diameter and number were used. The AFP score was calculated using the simplified algorithm described by Duvoux et al.\(^6\).

**Postoperative immunosuppression**

The standard immunosuppression regimen was based on a triple immunosuppression regimen based on calcineurin inhibitors, mycophenolic acid and steroids immediately after transplantation. None of the patients received induction therapy. In selected cases, a mammalian target of rapamycin inhibitor was added to the therapy no earlier than four weeks after transplantation.

**HCC-specific follow-up**

For specific HCC follow-up after transplantation, AFP levels were measured at least twice yearly combined with an abdominal ultrasound. MRI and CT scans were routinely performed once a year in the first 5 years after transplantation and whenever suspicious AFP levels or ultrasound findings were noted.

**Statistical analyses**

Data are presented as the mean and standard deviation (normally distributed variables) or as the median and lower and upper quartile (nonnormally distributed variables). For categorical variables, absolute and relative frequencies are given. The analyses were performed using R ver. 3.6 (R-Core Team). The Shapiro-Wilk test was used to prove a Gaussian distribution. To compare continuous variables, either the t-test or the Wilcoxon rank-sum test was chosen. For categorical variables, Fisher’s exact test was carried out. Patient survival is demonstrated on Kaplan-Meier curves with the log-rank test. Cox regression and logistic regression were used for multivariate analyses. A p-value less than 0.05 was considered significant.

**Results**

**Patient demographics**

A total of 120 patients (22 females and 98 males) were included in the analysis, with a median age of 61 years (Q1, Q3: 54.7, 65.4). Twenty-six patients underwent transplantation before the MELD scoring
system was implemented in Germany. The calculated median MELD score was 11 (Q1, Q3: 8, 15). The most frequent causes of liver cirrhosis were alcoholic liver disease (ALD) and viral hepatitis (n=75 and 21, respectively). The median waiting time was 222 days (Q1, Q3: 72.5, 347 days) (Table 1).

Table 1: Patient Demographics
|                          | [ALL] N=120 | N  |
|--------------------------|-------------|-----|
| Age                      | 61 [54.7;65.4] | 120 |
| <65                      | 91 (75.8%)  |     |
| >65                      | 29 (24.2%)  |     |
| Sex:                     |             | 120 |
| f                        | 22 (18.3%)  |     |
| m                        | 98 (81.7%)  |     |
| Disease                  |             |     |
| ALD                      | 75 (62.5%)  |     |
| HCV                      | 14 (11.7%)  |     |
| HBV                      | 7 (5.8%)    |     |
| Cryptogen                | 12 (10%)    |     |
| Other                    | 12 (10%)    |     |
| AFP (ng/ml)              | 8.00 [4.10;70.0] | 105 |
| Waiting_time (days)      | 212 [72.5;347] | 120 |
| D (mm)                   | 33.2 (20.8) | 120 |
| MELD:                    | 11 [8; 15]  | 97  |
| Meld <= 15               | 71 (73.2%)  |     |
| Meld = 15 - 30           | 17 (17.5%)  |     |
| Meld > 30                | 9 (9.28%)   |     |
| preTreat:                |             | 120 |
| no pre Treatment         | 45 (37.5%)  |     |
| pre Treatment            | 75 (62.5%)  |     |
| N:                       |             | 100 |
| N = 1                    | 59 (59.0%)  |     |
| N = 1 - 3                | 30 (30.0%)  |     |
| N > 3                    | 11 (11.0%)  |     |
| Grade:                   |             | 59  |
| 1                        | 23 (39.0%)  |     |
ALD: Alcoholic liver disease; HCV: Hepatitis C virus; HBV: Hepatitis B virus; AFP: Alpha-feto protein in ng/ml; D: Diameter of the largest tumor in mm; MELD: Model of end-stage liver disease; N: Number of tumors; MC: Milan Criteria; UTS: Up-to-seven Criteria; * Missing AFP values for 15 patients. Data are shown as the average and standard deviation (round brackets) for normally distributed data and as the median and quantiles (square brackets) for nonnormally distributed data.

**HCC diagnosis**

Eighty-nine patients received a diagnosis of HCC prior to transplantation based on a biopsy or MRI and CT scan, and the diagnosis was proven by postoperative pathology. Incidental HCC was detected in 31 patients according to the postoperative pathological examination. In our population, biopsy was performed preoperatively in 46 cases, proving HCC in 36 patients with 78.2% accuracy, followed by MRI with 68.6% accuracy (35 out of 51 patients) and CT with 64.3% accuracy (72 out of 112 patients). In total, 62.5% of all patients received transarterial chemoembolisation as bridging therapy, followed by radio frequency ablation or both. According to the postoperative histological results, 74 of 120 patients met the MC, 86 patients met the UTS criteria, and 85 patients met the Asan criteria. Out of 46 MC exceeding patients, 12 patients fulfilled UTS and 11 patients fulfilled the Asan criteria.

The AFP score could be calculated only for 105 patients due to the missing AFP values of 15 patients. A total of 79 patients had an AFP score equal to or less than 2. Only five patients exceeding the MC had an
AFP score equal to or less than 2.

**HCC recurrence-free survival**

Seventeen of the 120 patients (14.2%) developed HCC recurrence after a median of 28 months following transplantation (range 5-63 months). According to the univariate analyses, the parameters sex, age (≤ or >65 years), underlying disease, MELD score and pretreatment were not associated with HCC recurrence in our cohort. Only the AFP level (p=0.009), number of tumors (p=0.012), maximum diameter of the largest tumor (p=0.015), and tumor grade (p=0.045) were related to HCC recurrence.

Four of 74 (5.4%) patients fulfilled the MC criteria, four of 86 (4.7%) patients met the UTS criteria, and five of 85 (5.9%) patients fulfilled the Asan criteria and developed HCC recurrence. Five of 79 (6.3%) patients with an AFP score of 2 or less experienced HCC recurrence. These criteria were highly significant in the distinction between patients according to disease recurrence (MC: p=0.001, UTS criteria: p<0.001, Asan criteria: p<0.001, AFP score p=0.009). For the prediction of HCC recurrence, the sensitivity and specificity for the MC were 76% and 68%, respectively; for the UTS criteria, 76% and 80%, respectively; for the Asan criteria, 71% and 78%, respectively; and for the AFP score, 71% and 84%, respectively (Table 2). However, in the multivariate analyses, none of the parameters nor the scoring systems reached statistical significance (data not shown). According to the Kaplan-Meier curves, patients fulfilling UTS but exceeding the MC showed no significant changes in HCC recurrence (Figure 1).

**Table 2: Univariate Analyses for HCC Recurrence**
|                      | HCC N=17 | no HCC N=103 | p.overall |
|----------------------|----------|--------------|-----------|
| **age65:**           |          |              | 0.357     |
| <65                  | 11 (64.7%) | 80 (77.7%)   |           |
| >65                  | 6 (35.3%)  | 23 (22.3%)   |           |
| **sex:**             |          |              | 0.735     |
| f                    | 2 (11.8%)  | 20 (19.4%)   |           |
| m                    | 15 (88.2%) | 83 (80.6%)   |           |
| **AFP (ng/ml):**     | 165 [6.70;435] | 7.10 [4.00;39.1] | 0.009    |
| Waiting-time (days)  | 230 [31.0;394] | 211 [75.5;344] | 0.934    |
| **D (mm):**          | 43.4 (20.0) | 31.5 (20.6)  | 0.035     |
| **MELD:**            |          |              | 1.000     |
| Meld <= 15           | 12 (80.0%) | 59 (72.0%)   |           |
| Meld = 15 - 30       | 2 (13.3%)  | 15 (18.3%)   |           |
| Meld > 30            | 1 (6.67%)  | 8 (9.76%)    |           |
| **preTreat:**        |          |              | 1.000     |
| no pre Treatment     | 6 (35.3%)  | 39 (37.9%)   |           |
| pre Treatment        | 11 (64.7%) | 64 (62.1%)   |           |
| **N:**               |          |              | 0.012     |
| N = 1                | 1 (12.5%)  | 58 (63.0%)   |           |
| N = 1 - 3            | 5 (62.5%)  | 25 (27.2%)   |           |
| N > 3                | 2 (25.0%)  | 9 (9.78%)    |           |
| **grade:**           |          |              | 0.045     |
| 1                    | 0 (0.00%)  | 23 (43.4%)   |           |
| 2                    | 5 (83.3%)  | 28 (52.8%)   |           |
| 3                    | 1 (16.7%)  | 2 (3.77%)    |           |
| Asan:                |          |              | <0.001    |
| Exceeding            | 12 (70.6%) | 23 (22.3%)   |           |
| Fulfilling           | 5 (29.4%)  | 80 (77.7%)   |           |
| **AFP Score:**       |          |              | <0.001    |
Overall survival

The overall survival rates were 76.7% for 1 year, 67.2% for 3 years and 55.6% for 5 years. In total, 53 patients died during the follow-up period, most of them (n=17) due to HCC recurrence. Fifteen patients died from sepsis and multiorgan failure. The third most common cause of death was cardiopulmonary complications. The univariate analyses of sex, age (≤ or > 65 years), primary disease, MELD score, pretreatment, tumor diameter, number of tumors, and grade showed no statistically significant difference between survivors and nonsurvivors. Only AFP levels (p<0.001) showed significant differences between the groups.

The 1-, 3- and 5-year survival rates for patients fullfilling the MC were 82%, 77%, and 69%, respectively; those for patients fullfilling the UTS criteria were 81%, 76% and 71%, respectively; those for patients fullfilling the Asan criteria were 81%, 74% and 70%, respectively; and those for patients with an AFP score ≤2 were 82%, 75% and 52%, respectively. Similar to HCC recurrence, the criteria were also highly significant regarding survival (MC: p=0.001 UTS criteria: p<0.001, Asan criteria: p<0.001, AFP score: p=0.002). The sensitivity and specificity were 57% and 76%, respectively, for the MC, 49% and 88%, respectively, for the UTS criteria, 47% and 85%, respectively, for the Asan criteria and 41% and 87%, respectively, for the AFP score (Table 3). Again, according to the Kaplan-Meier curves, patients fullfilling UTS but exceeding the MC showed no significant changes in survival (Figure 1). However, in the multivariate analyses, none of the parameters nor the scoring systems reached statistical significance (data not shown).

Table 3. Univariate Analyses of Survival

|                | > 2 (70.6%) | ≤ 2 (29.4%) | MC: 0.001 |
|----------------|-------------|-------------|-----------|
| Exceeding      | 13 (76.5%)  | 33 (32.0%)  |           |
| Fulfilling     | 4 (23.5%)   | 70 (68.0%)  |           |
| UTS:           |             |             | <0.001    |
| Exceeding      | 13 (76.5%)  | 21 (20.4%)  |           |
| Fulfilling     | 4 (23.5%)   | 82 (79.6%)  |           |

AFP: Alpha-feto protein in ng/ml; D: Diameter of the largest tumor in mm; MELD: Model of end-stage liver disease; N: Number of tumors; MC: Milan Criteria; UTS: Up-to-seven Criteria. Data are shown as the average and standard deviation (round brackets) for normally distributed data and as the median and quantiles (square brackets) for nonnormally distributed data.
|                | Non Survivor N=53 | Survivor N=67 | p.overall |
|----------------|-------------------|---------------|-----------|
| age65:         |                   |               | 0.248     |
| <65            | 37 (69.8%)        | 54 (80.6%)    |           |
| >65            | 16 (30.2%)        | 13 (19.4%)    |           |
| sex:           |                   |               | 1.000     |
| f              | 10 (18.9%)        | 12 (17.9%)    |           |
| m              | 43 (81.1%)        | 55 (82.1%)    |           |
| AFP (ng/ml)    | 36.1 [5.40;234]   | 6.20 [3.50;26.5] | <0.001 |
| Waiting_time (days) | 236 [77.0;370] | 198 [64.5;316] | 0.319     |
| D (mm)         | 36.8 (20.1)       | 30.3 (21.1)   | 0.091     |
| MELD:          |                   |               | 0.703     |
| Meld <= 15     | 29 (69.0%)        | 42 (76.4%)    |           |
| Meld = 15 - 30 | 9 (21.4%)         | 8 (14.5%)     |           |
| Meld > 30      | 4 (9.52%)         | 5 (9.09%)     |           |
| preTreat:      |                   |               | 0.319     |
| no pre Treatment | 23 (43.4%)    | 22 (32.8%)    |           |
| pre Treatment  | 30 (56.6%)        | 45 (67.2%)    |           |
| N:             |                   |               | 0.109     |
| N = 1          | 18 (48.6%)        | 41 (65.1%)    |           |
| N = 1 - 3      | 12 (32.4%)        | 18 (28.6%)    |           |
| N > 3          | 7 (18.9%)         | 4 (6.35%)     |           |
| grade:         |                   |               | 0.559     |
| 1              | 8 (32.0%)         | 15 (44.1%)    |           |
| 2              | 15 (60.0%)        | 18 (52.9%)    |           |
| 3              | 2 (8.00%)         | 1 (2.94%)     |           |
| Asan:          |                   |               | <0.001    |
| Exceeding      | 25 (47.2%)        | 10 (14.9%)    |           |
| Fulfilling     | 28 (52.8%)        | 57 (85.1%)    |           |
| AFP Score:     |                   |               | 0.002     |
| MC:       | ≥ 2 | < 2 |
|-----------|-----|-----|
| Exceeding | 30 (56.6%) | 16 (23.9%) |
| Fulfilling | 23 (43.4%) | 51 (76.1%) |
| UTS:      | ≥ 2 | < 2 |
| Exceeding | 26 (49.1%) | 8 (11.9%) |
| Fulfilling | 27 (50.9%) | 59 (88.1%) |

AFP: Alpha-feto protein in ng/ml; D: Diameter of the largest tumor in mm; MELD: Model of end-stage liver disease; N: Number of tumors; MC: Milan Criteria; UTS: Up-to-seven Criteria. Data are shown as the average and standard deviation (round brackets) for normally distributed data and as the median and quantiles (square brackets) for nonnormally distributed data.

Discussion

HCC is the most studied primary tumor entity for the indication of liver transplantation. Because of the gap between the numbers of suitable donors and those of patients on the waiting list, transplantation should only be performed in patients who benefit most from organ transplantation. These patients can only be identified by clear guidelines and objective scoring systems.

The MC are widely used for the selection of patients and are also embedded in the MELD-based organ allocation programs in \(^1\),\(^2\). Patients beyond the MC can be transplanted based on extended allocation policies \(^9\),\(^10\). However, the limit for the exclusion of patients with advanced tumors from liver transplantation should be defined since the increase in tumor burden is related to a poor prognosis following transplantation \(^11\),\(^12\).

The current practice to prove the LTx indication is based on radiological findings such as tumor diameter and number of hepatic nodules. However, the accuracy of pretransplant imaging in cirrhotic liver has been questioned in several studies when compared with posttransplant histopathology \(^13\),\(^8\).

To avoid these problems and to determine the real tumor load at the time of LTx, we analyzed our patients based on histopathological results. Then, we retrospectively classified the patients into established indication criteria for patients with HCC and assessed postoperative survival.

In the same manner, Lee et al. investigated the basic histopathological features of patients with HCC in living donor liver transplantation and introduced the so-called Asan criteria. Meeting the Asan criteria...
(largest tumor diameter ≤5 cm, number of tumors ≤6), they could achieve a 5-year overall survival of 76.3%, which was nonsignificantly higher than the 5-year survival if meeting the MC in their population.

In our patients, who were transplanted following deceased donation, we observed similar survival curves for the patients fulfilling the MC or UTS or Asan criteria. Current data on the outcome of patients fulfilling the MC show overall 1-, 3- and 5-year survival rates of 85-93%, 75-81%, and 68-73%, respectively 14,15. Our data were comparable to international data showing 1-, 3- and 5-year overall survival rates of 82%, 77%, and 69%, respectively, within the MC. Using extension criteria such as the AFP score, UTS and Asan, we were able to show similar results 16,8,6,17.

Interestingly, in our study, patients with an AFP score equal to or less than 2 showed a 5-year survival rate of 52%, a significantly worse long-term survival compared to patients in other groups. This difference is most likely due to the missing AFP data of 15 patients.

An independent factor influencing postoperative survival after transplantation is the recurrence of HCC. In our analysis, HCC recurrence occurred after a median follow-up period of 28 months after transplantation. All of these patients died during the follow-up period. The univariate analysis determined a significant influence of the AFP level, number of tumors, maximum diameter of the largest tumor and tumor grade on the outcome after LTx.

Whether AFP is a reliable marker is still an ongoing topic, and the cutoff AFP level as a contraindication for LTx has not been determined 1. In our study, only 21 patients with a maximum AFP level higher than 100 ng/ml and only ten patients with an AFP level higher than 500 ng/ml were transplanted, showing no unique survival or recurrence features (data not shown). Thus, we cannot assess a cutoff AFP level for contraindication for LTx in concordance with the current guidelines 5.

In our detection of HCC recurrence, established clinical scores, such as the MC, UTS criteria, Asan criteria and AFP score, showed similar prediction for HCC recurrence following LTx. Concerning the two endpoint parameters together (overall survival and recurrence), the best performance with sensitivity and specificity was achieved when considering the UTS criteria.

Using UTS as the extension criteria for LTx, we could add 12 patients fulfilling UTS, which were beyond the MC and were theoretically excluded from regular allocation policy. Interestingly, the patients fulfilling the UTS but exceeding the MC in our population showed similar survival and recurrence rates compared to the patients fulfilling MC only. Thus, the extension of the MC using the UTS criteria for the indication for LTx must be considered in standard care.

The most important limitation of this study is its retrospective design. However, the sensitivity of preoperative imaging for focal lesions in cirrhotic tissue is still limited 18. The consideration of tumor biology and the underlying disease need to be included in the indication for LTx. New strategies, such as the detection of biomarkers in tumor tissue as well as in the sera of patients with HCC, could help identify new parameters for an indication for LTx in patients with HCC 19,20.
Conclusions

In conclusion, we were able to confirm the indication criteria for liver transplantation (MC, UTS criteria, Asan criteria, AFP score) based on the postoperative histopathological results in our population. In terms of specificity and sensitivity, the UTS criteria are superior to the other criteria in terms of overall and recurrence free survival. Consequently, we consider using UTS criteria as the standard criterion for LTx indication.

List Of Abbreviations

MC: milan criteria
LTx: liver transplantation
HCC: hepatocellular carcinoma
UTS: up-to-seven
AFP: alpha-fetoprotein
MELD: model for end-stage liver disease
ALD: alcoholic liver disease

Declarations

Ethics approval and consent to participate
This retrospective database analysis study was approved by the institutional review board of University of Leipzig Ethics Committee (ethical committee application number: 078-14-10032014), and the requirement to obtain informed consent was waived.

Consent for publication
All authors consent to the publication.

Availability of data and material
The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Competing interests
The authors declare no competing interests.
**Funding**
Not applicable

**Authors’ contributions**
All Authors read and approved the manuscript

MHM and PF have designed the study, collected data, analyzed the data and wrote the manuscript.

AK has designed the study, collected and analyzed the data.

UG has analyzed the data and edited the manuscript.

KS and HMH have collected the data and edited the manuscript.

HMT has designed the study, analyzed data, and edited the manuscript.

MB has designed the study, analyzed data and wrote the manuscript.

**Acknowledgements**
Not applicable

**Literature**

1. Umgelter A, Hapfelmeier A, Kopp W, et al. Disparities in Eurotransplant liver transplantation wait-list outcome between patients with and without model for end-stage liver disease exceptions. *Liver Transpl.* 2017;23(10):1256-1265. doi:10.1002/lt.24805

2. Northup PG, Intagliata NM, Shah NL, Pelletier SJ, Berg CL, Argo CK. Excess mortality on the liver transplant waiting list: unintended policy consequences and Model for End-Stage Liver Disease (MELD) inflation. *Hepatology.* 2015;61(1):285-291. doi:10.1002/hep.27283

3. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. *N Engl J Med.* 1996;334(11):693-699. doi:10.1056/NEJM199603143341104

4. Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. *Lancet Oncol.* 2009;10(1):35-43. doi:10.1016/S1470-2045(08)70284-5

5. Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. *Hepatology.* 2018;68(2):723-750. doi:10.1002/hep.29913

6. Duvoux C, Roudot-Thoraval F, Decaens T, et al. Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria. *Gastroenterology.* 2012;143(4):986-94.e3; quiz e14-5. doi:10.1053/j.gastro.2012.05.052
7. Pavel M-C, Fuster J. Expansion of the hepatocellular carcinoma Milan criteria in liver transplantation: Future directions. *World J Gastroenterol.* 2018;24(32):3626-3636. doi:10.3748/wjg.v24.i32.3626

8. Lee S-G, Hwang S, Moon D-B, et al. Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one large-volume center. *Liver Transpl.* 2008;14(7):935-945. doi:10.1002/lt.21445

9. European Association for the Study of the Liver. Electronic address: easlooffice@easlooffice.eu. EASL Clinical Practice Guidelines: Liver transplantation. *J Hepatol.* 2016;64(2):433-485. doi:10.1016/j.jhep.2015.10.006

10. Rudnick SR, Russo MW. Liver transplantation beyond or downstaging within the Milan criteria for hepatocellular carcinoma. *Expert Rev Gastroenterol Hepatol.* 2018;12(3):265-275. doi:10.1080/17474124.2018.1417035

11. Strassburg CP. HCC-Associated Liver Transplantation - Where Are the Limits and What Are the New Regulations? *Visc Med.* 2016;32(4):263-271. doi:10.1159/000446385

12. Parikh ND, Yopp A, Singal AG. Controversies in criteria for liver transplantation in hepatocellular carcinoma. *Curr Opin Gastroenterol.* 2016;32(3):182-188. doi:10.1097/MOG.0000000000000264

13. Herden U, Schoening W, Pratschke J, et al. Accuracy of Pretransplant Imaging Diagnostic for Hepatocellular Carcinoma: A Retrospective German Multicenter Study. *Can J Gastroenterol Hepatol.* 2019;2019:1-9. doi:10.1155/2019/8747438

14. Kositamongkol P, Sanphasitvong V, Sirivatanauksom Y, et al. Outcome of Liver Transplantation in Hepatocellular Carcinoma Patients at Siriraj Hospital. *Transplant Proc.* 2017;49(5):1114-1117. doi:10.1016/j.transproceed.2017.03.047

15. Commander SJ, Shaw B, Washburn L, Yoeli D, Rana A, Goss JA. A long-term experience with expansion of Milan criteria for liver transplant recipients. *Clin Transplant.* April 2018:e13254. doi:10.1111/ctr.13254

16. Lei J-Y, Wang W-T, Yan L-N. Up-to-seven criteria for hepatocellular carcinoma liver transplantation: a single center analysis. *World J Gastroenterol.* 2013;19(36):6077-6083. doi:10.3748/wjg.v19.i36.6077

17. Varona MA, Soriano A, Aguirre-Jaime A, et al. Risk factors of hepatocellular carcinoma recurrence after liver transplantation: accuracy of the alpha-fetoprotein model in a single-center experience. *Transplant Proc.* 47(1):84-89. doi:10.1016/j.transproceed.2014.12.013

18. Chou R, Cuevas C, Fu R, et al. Imaging Techniques for the Diagnosis of Hepatocellular Carcinoma. *Ann Intern Med.* 2015;162(10):697. doi:10.7326/M14-2509

19. Morgul MH, Klunk S, Anastasiadou Z, et al. Diagnosis of HCC for patients with cirrhosis using miRNA profiles of the tumor-surrounding tissue – A statistical model based on stepwise penalized logistic regression. *Exp Mol Pathol.* 2016;101(2):165-171. doi:10.1016/j.yexmp.2016.07.014

20. Hung C-H, Hu T-H, Lu S-N, et al. Circulating microRNAs as biomarkers for diagnosis of early hepatocellular carcinoma associated with hepatitis B virus. *Int J Cancer.* 2016;138(3):714-720. doi:10.1002/ijc.29802
**Figures**

**Figure 1**

Kaplan Meier Curves for the HCC recurrence (A) and patients survival (B). Red line for patient exceeding MC and UTS, blue line for patients fulfilling MC and UTS, green line for patients exceeding MC but fulfilling UTS.